Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study

 TTP
(N = 463)
PPP
(N = 439)
Age, years, mean (SD)32.2 (4.1)32.1 (4.0)
BMI, kg/m2, mean (SD)23.4 (3.6)23.3 (3.2)
AMH, ng/mL, mean (SD)3.6 (2.3)3.6 (2.3)
Total r-hFSH dose, IU
 Mean (SD)1651.2 (506.7)1629.4 (479.9)
 Median1516.01500.0
 Range750.0–3825.0750.0–3825.0
Duration of FSH stimulation, days
 Mean (SD)9.5 (1.7)9.5 (1.7)
 Median9.09.0
 Range4.0–17.05.0–16.0
GnRH antagonist protocol
 Missing, n (%)1 (0.2)0
 No GnRH antagonist used, n (%)8 (1.7)0
 Cetrorelix, n (%)116 (25.1)115 (26.2)
  Days, mean (SD)6.2 (1.9)6.3 (1.9)
 Ganirelix, n (%)338 (73.0)324 (73.8)
  Days, mean (SD)5.0 (1.7)5.0 (1.7)
Serum estradiol prior to trigger, ng/L, mean (SD)1362.0 (969.5)1380.6 (968.8)
Endometrial thickness prior to trigger, mm, mean (SD)9.7 (2.0)9.8 (2.0)
Used for follicular maturation triggering
 Missing, n (%)8 (1.7)6 (1.4)
 Recombinant hCG, n (%)196 (42.3)183 (41.7)
 Urinary hCG, n (%)198 (42.8)190 (43.3)
 GnRH agonist, n (%)61 (13.2)60 (13.7)
  1. AMH anti-Müllerian hormone, BMI body mass index, GnRH gonadotropin-releasing hormone, hCG human chorionic gonadotropin, PPP per protocol population, r-hFSH recombinant human follicle-stimulating hormone, SD standard deviation, TTP total treated population